Biogen

BIIB Q2 2025 Earnings

Reported Jul 31, 2025 at 6:13 AM ET · SEC Source

Q2 25 EPS

$5.47

BEAT +41.31%

Est. $3.87

Q2 25 Revenue

$2.65B

BEAT +13.90%

Est. $2.32B

vs S&P Since Q2 25

+25.4%

BEATING MARKET

BIIB +39.4% vs S&P +14.0%

Market Reaction

Did BIIB Beat Earnings? Q2 2025 Results

Biogen delivered a standout second quarter for 2025, posting earnings per share of $5.47 against a consensus estimate of $3.87, a 41.31% beat, while revenue of $2.65 billion topped expectations by 13.90% and grew 7.3% year over year. The headline dri… Read more Biogen delivered a standout second quarter for 2025, posting earnings per share of $5.47 against a consensus estimate of $3.87, a 41.31% beat, while revenue of $2.65 billion topped expectations by 13.90% and grew 7.3% year over year. The headline driver behind the blowout quarter was a surge in contract manufacturing revenue, which more than doubled to $244.60 million as Biogen accelerated batch production ahead of planned fourth-quarter plant maintenance shutdowns. Launch products added meaningful momentum: SKYCLARYS contributed approximately $130.00 million globally, ZURZUVAE revenue of $46.40 million rose 68% sequentially, and LEQEMBI U.S. In-market sales reached approximately $63.00 million with 20% sequential growth, a signal worth watching as broader market sentiment turns more constructive on large-cap earnings. Looking ahead, Biogen raised its full-year 2025 non-GAAP diluted EPS guidance to $15.50 to $16.00 and now expects total revenue to be approximately flat at constant currency versus 2024, a notable improvement from its prior forecast of a mid-single digit decline.

Key Takeaways

  • Strong sequential growth across launch products: LEQEMBI, SKYCLARYS, and ZURZUVAE
  • Contract manufacturing revenue more than doubled year-over-year due to accelerated batch production ahead of Q4 maintenance shutdowns
  • Resilience in U.S. MS business driven by VUMERITY demand and approximately $75 million in favorable gross-to-net adjustments and inventory timing
  • Anti-CD20 therapeutic program revenue grew 5% year-over-year
  • Fit for Growth cost discipline program generating savings
  • Favorable effective tax rate reduction from 15.9% to 13.5% Non-GAAP
24/7 Wall St

BIIB YoY Financials

Q2 2025 vs Q2 2024, source: SEC Filings

24/7 Wall St

BIIB Revenue by Segment

With YoY comparisons, source: SEC Filings

Q1 25 Q1 26
24/7 Wall St

BIIB Revenue by Geography

With YoY comparisons, source: SEC Filings

Q1 25 Q1 26

“We delivered another quarter of strong execution against our strategy to transform our portfolio and build the new Biogen. Our performance reflects robust financial results, ongoing cost discipline, continued growth of our launch products, and meaningful strides expanding and advancing our late-stage pipeline. We are now progressing salanersen to registrational studies in SMA following exciting interim Phase 1b results, and have initiated all three Phase 3 studies for felzartamab in rare kidney disease. These achievements reinforce our commitment to building a stronger company, with the potential for sustainable growth and long-term value for our shareholders.”

— Christopher A. Viehbacher, Q2 2025 Earnings Press Release